Skip to main content
. Author manuscript; available in PMC: 2013 Apr 1.
Published in final edited form as: Stroke. 2012 Feb 23;43(4):952–957. doi: 10.1161/STROKEAHA.111.643072

Table 5.

Effect of Hormone Therapy on Ischemic Stroke Risk by Change in Tissue Factor Pathway Inhibitor and Activated Protein C Resistance

First Tertile Second Tertile Third Tertile
Change Value OR (95% CI) Change Value OR (95% CI) Change Value OR (95% CI) P Value for Interaction*
Total TFPI, ng/mL < -17.5 1.38 (0.65, 2.94) -17.6 - -2.4 2.06 (1.16, 3.64) >-2.4 2.03 (1.08, 3.81) 0.769
Free TFPI, ng/mL < -4.1 2.10 (1.08, 4.09) -4.1 - 0.6 1.27 (0.72, 2.24) > 0.6 2.62 (1.46. 4.71) 0.452
TFPI Activity, % < -25.0 1.29 (0.59, 2.80) -25 - -4 2.07 (1.14, 3.76) > -4.0 1.74 (0.93, 3.28) 0.714
nAPCsr, ratio < -0.1 2.29 (1.08, 4.86) -0.2 - 1.5 1.09 (0.54, 2.22) > 1.5 2.60 (1.14, 5.90) 0.971
*

P values for interaction in combined trials of active treatment/placebo X change in biomarker adjusting for hysterectomy status, baseline level of biomarkers, and the same covariates as in Table 3, based on 317 cases and 465 controls for TFPI and 220 cases and 330 controls for nAPCsr. Tertile cutpoints for change are derived from controls.